Why Amgen Stock Was Crushing It on Wednesday
Key Points
The biotech and pharmaceutical mainstay posted its third-quarter results.
It was a beat-and-raise quarter that featured double-digit growth on the top line.
- 10 stocks we like better than Amgen ›
One of the healthier stocks in the healthcare field Wednesday was Amgen (NASDAQ: AMGN). The biotech and pharmaceutical company published its third-quarter results the previous day after market close, and investors were obviously pleased. In mid-session trading Wednesday they were pushing the stock's price up by more than 8%.
Good for what ails a portfolio
The quarter saw Amgen lift its total revenue by 12% year over year to $9.6 billion, fueled by double-digit increases in the sales of key drugs. Net income not according to generally accepted accounting principles (GAAP) also rose, albeit more modestly. It ticked up by 1% to just under $3.06 billion, or $5.64 per share.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Image source: Getty Images.
Both line items landed well above the consensus analyst estimates. Pundits tracking Amgen stock believed the company would earn only $8.98 billion on the top line and post a non-GAAP (adjusted) net profit of $5.04.
Amgen attributed the better-than-expected performance to volume growth. As for the future, it quoted CEO Robert Bradway as saying, "With disciplined investment and a pipeline of first-in-class medicines, we're focused on expanding access, advancing innovation, and sustaining long-term growth."
Modest but meaningful raises
Surely with that in mind, Amgen raised its full-year 2025 guidance for both revenue and adjusted profitability.
For the former, it's now expecting to earn $35.8 billion to $36.6 billion; the previous guidance was for $35 billion to $36 billion. The new adjusted net income forecast is $20.60 to $21.40 per share, where formerly it stood at $20.20 to $21.30.
Should you invest $1,000 in Amgen right now?
Before you buy stock in Amgen, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amgen wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $589,424!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,217,942!*
Now, it’s worth noting Stock Advisor’s total average return is 1,054% — a market-crushing outperformance compared to 193% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of November 3, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen. The Motley Fool has a disclosure policy.
Recommended Articles
